328 related articles for article (PubMed ID: 10945627)
1. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ
Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627
[TBL] [Abstract][Full Text] [Related]
2. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.
Wu K; Knox R; Sun XZ; Joseph P; Jaiswal AK; Zhang D; Deng PS; Chen S
Arch Biochem Biophys; 1997 Nov; 347(2):221-8. PubMed ID: 9367528
[TBL] [Abstract][Full Text] [Related]
3. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
4. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
5. CB 1954: from the Walker tumor to NQO2 and VDEPT.
Knox RJ; Burke PJ; Chen S; Kerr DJ
Curr Pharm Des; 2003; 9(26):2091-104. PubMed ID: 14529407
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model.
Wu K; Eng E; Knox R; Chen S
Arch Biochem Biophys; 2001 Jan; 385(1):203-8. PubMed ID: 11361019
[TBL] [Abstract][Full Text] [Related]
7. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
[TBL] [Abstract][Full Text] [Related]
8. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs.
Celli CM; Tran N; Knox R; Jaiswal AK
Biochem Pharmacol; 2006 Jul; 72(3):366-76. PubMed ID: 16765324
[TBL] [Abstract][Full Text] [Related]
9. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
10. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity.
Friedlos F; Biggs PJ; Abrahamson JA; Knox RJ
Biochem Pharmacol; 1992 Nov; 44(9):1739-43. PubMed ID: 1449531
[TBL] [Abstract][Full Text] [Related]
12. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
Chen S; Knox R; Lewis AD; Friedlos F; Workman P; Deng PS; Fung M; Ebenstein D; Wu K; Tsai TM
Mol Pharmacol; 1995 May; 47(5):934-9. PubMed ID: 7746280
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.
Beall HD; Mulcahy RT; Siegel D; Traver RD; Gibson NW; Ross D
Cancer Res; 1994 Jun; 54(12):3196-201. PubMed ID: 8205540
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2).
Friedlos F; Jarman M; Davies LC; Boland MP; Knox RJ
Biochem Pharmacol; 1992 Jul; 44(1):25-31. PubMed ID: 1385952
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
Seville S; Phillips RM; Shnyder SD; Wright CW
Bioorg Med Chem; 2007 Oct; 15(19):6353-60. PubMed ID: 17643990
[TBL] [Abstract][Full Text] [Related]
16. Phthalimide analogs of CB 1954: synthesis and bioactivation.
Mehta LK; Hobbs S; Chen S; Knox RJ; Parrick J
Anticancer Drugs; 1999 Sep; 10(8):777-83. PubMed ID: 10573210
[TBL] [Abstract][Full Text] [Related]
17. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity.
Gibson NW; Hartley JA; Butler J; Siegel D; Ross D
Mol Pharmacol; 1992 Sep; 42(3):531-6. PubMed ID: 1406604
[TBL] [Abstract][Full Text] [Related]
18. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).
Knox RJ; Friedlos F; Boland MP
Cancer Metastasis Rev; 1993 Jun; 12(2):195-212. PubMed ID: 8375021
[TBL] [Abstract][Full Text] [Related]
19. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
Helsby NA; Wheeler SJ; Pruijn FB; Palmer BD; Yang S; Denny WA; Wilson WR
Chem Res Toxicol; 2003 Apr; 16(4):469-78. PubMed ID: 12703963
[TBL] [Abstract][Full Text] [Related]
20. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
